Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 5.6% in October

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,340,000 shares, an increase of 5.6% from the October 15th total of 4,110,000 shares. Based on an average daily trading volume, of 524,700 shares, the short-interest ratio is presently 8.3 days. Currently, 7.9% of the shares of the stock are short sold.

Insider Activity at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This represents a 11.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.93% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $37,000. Quest Partners LLC bought a new stake in Agios Pharmaceuticals in the second quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. increased its position in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the period. CWM LLC raised its holdings in Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals in the 3rd quarter worth about $146,000.

Agios Pharmaceuticals Trading Down 2.9 %

Shares of NASDAQ:AGIO opened at $53.78 on Monday. Agios Pharmaceuticals has a 12-month low of $20.96 and a 12-month high of $62.58. The stock’s 50-day moving average price is $46.44 and its 200-day moving average price is $43.94. The stock has a market capitalization of $3.07 billion, a P/E ratio of 4.73 and a beta of 0.75.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on AGIO shares. Scotiabank boosted their price objective on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research note on Friday, November 1st. Finally, Raymond James reaffirmed an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $52.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.